What’s the current market cap for Praxis Precision Medicines stock?

Praxis Precision Medicines (PRAX) has a market cap of $9.3B as of June 02, 2026.

What is the P/E ratio for Praxis Precision Medicines stock?

The price to earnings (P/E) ratio for Praxis Precision Medicines (PRAX) stock is 0 as of June 02, 2026.

Does Praxis Precision Medicines stock pay dividends?

No, Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders as of June 02, 2026.

When is the next Praxis Precision Medicines dividend payment date?

Praxis Precision Medicines (PRAX) stock does not pay dividends to its shareholders.

What is the beta indicator for Praxis Precision Medicines?

Praxis Precision Medicines (PRAX) has a beta rating of 2.78. This means that it is more volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 2 would indicate the stock moves twice as much as the market.

Buy Praxis Precision Medicines stock | $PRAX Share Price

PRAX drops after its Phase 2/3 POWER1 trial of vormatrigine in focal onset seizures failed to meet its primary endpoint on 06/01/2026, prompting a pause in POWER2 enrollment.

5 hours ago·Lightyear AI

13:30

09:10

04:45

00:25

20:00

About Praxis Precision Medicines

Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. It is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company applies genetic insights to the discovery and development of therapies for neurological disorders through two proprietary platforms: Cerebrum and Solidus. It has established a diversified, multimodal CNS portfolio with four clinical-stage product candidates across movement disorders and epilepsy, which include Ulixacaltamide, Relutrigine, Vormatrigine, and Elsunersen. The firm operates in only one segment and is focused on discovering and developing therapies for CNS disorders.

Ticker

$PRAX

Sector

Health

Primary listing

NASDAQ

Employees

168

Headquarters

Boston, United States

Website

praxismedicines.com

PRAX Metrics

BasicAdvanced

$9.3bn

-$13.35

2.78

What the Analysts think about PRAX

Analyst ratings (Buy, Hold, Sell) for Praxis Precision Medicines stock.

Bulls say / Bears say

Cash, cash equivalents and marketable securities totaled USD 926.1 million as of December 31, 2025, and net proceeds of USD 621.2 million from a January 2026 follow-on public offering are expected to fund operations into 2028, providing a multi-year runway for its CNS pipeline.

Praxis announced positive topline results from two pivotal Phase 3 Essential3 studies of ulixacaltamide in essential tremor, with all primary and key secondary endpoints met across both studies, highlighting the strong efficacy profile of its lead asset.

On January 12, 2026, Reuters reported that Praxis expects to submit NDAs for ulixacaltamide in essential tremor and relutrigine in SCN2A/SCN8A developmental and epileptic encephalopathies by mid-February 2026, marking a key regulatory de-risking milestone.

Praxis reported a FY 2025 net loss of USD 303.3 million and a Q4 2025 net loss of USD 88.9 million, underscoring substantial cash burn without product revenues.

Shares outstanding rose to 27.86 million as of March 31, 2026 from 25.2 million at year-end 2025, reflecting dilution from a January 2026 follow-on public offering, which may pressure future EPS and shareholder value.

Praxis generated just USD 0.4 million in revenue in Q4 2025 and posted an EPS loss of USD 3.09, showing its ongoing dependence on financing and clinical milestones for value creation in the absence of meaningful product sales.

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.

PRAX Financial Performance

Revenues and expenses

QuarterlyAnnual

Q3 24

QoQ growth

Revenue

$37bn

-39.75%

Net income

$45bn

107.52%

Profit margin

37.65%

6.78%

PRAX Earnings Performance

Company profitability

QuarterlyAnnual

Q4 23

Q1 24

Q2 24

Q3 24

Q4 24

Actual

$3.69

$2.85

$2.45

$2.42

Expected

$3.55

$2.61

$2.05

$2.31

$3.94

Surprise

3.94%

9.20%

19.51%

4.63%

Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.

Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.

Buy $PRAX

Capital at risk

Market closed

Upcoming events

No upcoming events

Bulls say / Bears say

Praxis reported a FY 2025 net loss of USD 303.3 million and a Q4 2025 net loss of USD 88.9 million, underscoring substantial cash burn without product revenues.

Data summarised monthly by Lightyear AI. Last updated on 21 May 2026.